The Journal of Immunology, Vol 148, Issue 10 3165-3173, Copyright © 1992 by American Association of Immunologists

ARTICLES

Biologic activity of synthetic analogues of C5a anaphylatoxin

JA Ember, SD Sanderson, SM Taylor, M Kawahara and TE Hugli
Scripps Research Institute, Department of Immunology, La Jolla, CA 92037.

The C activation fragment C5a is the most potent plasma-derived chemotactic factor known. This humoral factor induces both neutrophil and macrophage activation at low nanomolar concentrations. We have synthesized a series of C-terminal C5a analogues that exhibit all of the characteristic biologic activities of C5a. These peptides apparently contain the effector site for C5a receptor-mediated cellular activation, but express only a fraction of the potency of intact C5a. We have demonstrated the following in vitro activities for these C5a peptides: 1) ileal (guinea pig) contraction; 2) platelet (guinea pig) activation; and 3) neutrophil (human) polarization and chemotaxis. The effect of C5a peptides in vivo was evaluated by measuring enhancement in vascular permeability. Although potencies of the most effective synthetic C5a analogues were on the order of 0.01 to 0.1% that of the natural factor, our biologic data confirm that the C5a peptides are full agonists of the intact factor and may be useful substitutes for intact C5a. Furthermore, our results indicate that elongation of the C5a analogues from 10 to 19 residues in length contributes little toward enhancing or decreasing potency of the synthetic C5a analogues. Replacement of residues in the effector region by D-amino acids or by introduction of a cyclic group to reduce flexibility of the backbone decreased potency of the analogues. Substitution of His 67 by Phe in the decapeptide C5a 65-74 resulted in a significant increase in potency of the C5a analogue. The marked enhancement in potency from replacing His 67 by Phe in analogue C5a peptides identifies an important hydrophobic subsite. We conclude that site-specific amino acid modifications in or near the C-terminal effector site sequence can diminish or optimize potency of the model C5a peptides. However, there apparently are subsites on folded C5a, from regions other than the C- terminal portion of the molecule, that contribute significant receptor interactions. These subsites must be identified and incorporated into C5a model peptide designs before expression of full potency by synthetic analogues of this factor will be realized.

This article has been cited by other articles:

				S. M. Waters, R. M. Brodbeck, J. Steflik, J. Yu, C. Baltazar, A. E. Peck, D. Severance, L. Y. Zhang, K. Currie, B. L. Chenard, et al. Molecular Characterization of the Gerbil C5a Receptor and Identification of a Transmembrane Domain V Amino Acid That Is Crucial for Small Molecule Antagonist Interaction J. Biol. Chem., December 9, 2005; 280(49): 40617 - 40623. [Abstract] [Full Text] [PDF]

				V. Wittamer, F. Gregoire, P. Robberecht, G. Vassart, D. Communi, and M. Parmentier The C-terminal Nonapeptide of Mature Chemerin Activates the Chemerin Receptor with Low Nanomolar Potency J. Biol. Chem., March 12, 2004; 279(11): 9956 - 9962. [Abstract] [Full Text] [PDF]

				M. Otto, H. Hawlisch, P. N. Monk, M. Muller, A. Klos, C. L. Karp, and J. Kohl C5a Mutants Are Potent Antagonists of the C5a Receptor (CD88) and of C5L2: POSITION 69 IS THE LOCUS THAT DETERMINES AGONISM OR ANTAGONISM J. Biol. Chem., January 2, 2004; 279(1): 142 - 151. [Abstract] [Full Text] [PDF]

				M. S. Huber-Lang, J. V. Sarma, S. R. McGuire, K. T. Lu, V. A. Padgaonkar, E. M. Younkin, R. F. Guo, C. H. Weber, E. R. Zuiderweg, F. S. Zetoune, et al. Structure-Function Relationships of Human C5a and C5aR J. Immunol., June 15, 2003; 170(12): 6115 - 6124. [Abstract] [Full Text] [PDF]

				Y. Shibuya, M. Shiokawa, H. Nishiura, T. Nishimura, N. Nishino, H. Okabe, K. Takagi, and T. Yamamoto Identification of Receptor-Binding Sites of Monocyte Chemotactic S19 Ribosomal Protein Dimer Am. J. Pathol., December 1, 2001; 159(6): 2293 - 2301. [Abstract] [Full Text] [PDF]

				S. Eglite, K. Pluss, and C. A. Dahinden Requirements for C5a Receptor-Mediated IL-4 and IL-13 Production and Leukotriene C4 Generation in Human Basophils J. Immunol., August 15, 2000; 165(4): 2183 - 2189. [Abstract] [Full Text] [PDF]

				K. Shimoya, A. Moriyama, N. Matsuzaki, I. Ogata, M. Koyama, C. Azuma, F. Saji, and Y. Murata Human placental cells show enhanced production of interleukin (IL)-8 in response to lipopolysaccharide (LPS), IL-1 and tumour necrosis factor (TNF)-{alpha}, but not to IL-6 Mol. Hum. Reprod., September 1, 1999; 5(9): 885 - 885. [Abstract] [Full Text] [PDF]

				T. Heller, M. Hennecke, U. Baumann, J. E. Gessner, A. Meyer zu Vilsendorf, M. Baensch, F. Boulay, A. Kola, A. Klos, W. Bautsch, et al. Selection of a C5a Receptor Antagonist from Phage Libraries Attenuating the Inflammatory Response in Immune Complex Disease and Ischemia/Reperfusion Injury J. Immunol., July 15, 1999; 163(2): 985 - 994. [Abstract] [Full Text] [PDF]

				M. Mizuno, K. Nishikawa, N. Okada, S. Matsuo, K. Ito, and H. Okada Inhibition of a Membrane Complement Regulatory Protein by a Monoclonal Antibody Induces Acute Lethal Shock in Rats Primed with Lipopolysaccharide J. Immunol., May 1, 1999; 162(9): 5477 - 5482. [Abstract] [Full Text] [PDF]

				T. Crass, R. S. Ames, H. M. Sarau, M. A. Tornetta, J. J. Foley, J. Kohl, A. Klos, and W. Bautsch Chimeric Receptors of the Human C3a Receptor and C5a Receptor (CD88) J. Biol. Chem., March 26, 1999; 274(13): 8367 - 8370. [Abstract] [Full Text] [PDF]

				S. P. Henry, P. C. Giclas, J. Leeds, M. Pangburn, C. Auletta, A. A. Levin, and D. J. Kornbrust Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 810 - 816. [Abstract] [Full Text]

				J. A. DeMartino, Z. D. Konteatis, S. J. Siciliano, G. V. Riper, D. J. Underwood, P. A. Fischer, and M. S. Springer Arginine 206 of the C5a Receptor Is Critical for Ligand Recognition and Receptor Activation by C-terminal Hexapeptide Analogs J. Biol. Chem., July 7, 1995; 270(27): 15966 - 15969. [Abstract] [Full Text] [PDF]